PE20200610A1 - Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales - Google Patents
Polipeptidos que antagonizan la senalizacion wnt en celulas tumoralesInfo
- Publication number
- PE20200610A1 PE20200610A1 PE2019002493A PE2019002493A PE20200610A1 PE 20200610 A1 PE20200610 A1 PE 20200610A1 PE 2019002493 A PE2019002493 A PE 2019002493A PE 2019002493 A PE2019002493 A PE 2019002493A PE 20200610 A1 PE20200610 A1 PE 20200610A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- isvd
- cdr1
- cdr2
- cdr3
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 230000011664 signaling Effects 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract 1
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 102000052547 Wnt-1 Human genes 0.000 abstract 1
- 108700020987 Wnt-1 Proteins 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Referido a un polipeptido que se fija a la proteina 5 de tipo receptor de lipoproteinas de baja densidad (LRP5), que comprende un dominio variable unico de inmunoglobulina (ISVD) seleccionado del grupo de: (i) un ISVD que comprende las siguientes secuencia de regiones determinantes de la complementariedad : CDR1:TYVMG (SEQ ID NO:1), CDR2: AISWSGGSTYYADSVKG (SEQ ID NO:2), CDR3: SRGTSTPSRASGVSRYDY (SEQ ID NO:3), (ii) un ISVD que comprende las secuencias: CDR1: RYAVA (SEQ ID NO:4), CDR2: AITWSSGRIDYADSVKG (SEQ ID NO:5), CDR3: DRRPRSTGRSGTGSPSTYDY (SEQ ID NO:6); (iii) un ISVD que comprende: CDR1: IGAMG (SEQ ID NO:7), CDR2: AVSSGGSTYYVDSVKG (SEQ ID NO:8), CDR3: ETGPYGPPKRDY (SEQ ID NO:9) y (iv) un ISVD que comprende: CDR1:INAMG (SEQ ID NO:10), CDR2: AVSSGGSTYYVDSVKG (SEQ ID NO:8), CDR3: ETGPYGPPKRDY (SEQ ID NO:9). Dicho polipeptido inhibe la via de senalizacion Wnt1/Wnt3a siendo util en el tratamiento del cancer de mama, cancer de pulmon, entre otros. Tambien se refiere a una molecula de acido nucleico que codifica el polipeptido, un vector de expresion, una celula huesped una composicion farmaceutica que comprende dicho polipeptido, un metodo de produccion y a un metodo de tratamiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17173782 | 2017-05-31 | ||
PCT/EP2018/064295 WO2018220080A1 (en) | 2017-05-31 | 2018-05-30 | Polypeptides antagonizing wnt signaling in tumor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20200610A1 true PE20200610A1 (es) | 2020-03-10 |
Family
ID=59021278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019002493A PE20200610A1 (es) | 2017-05-31 | 2018-05-30 | Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales |
Country Status (21)
Country | Link |
---|---|
US (2) | US11033636B2 (es) |
EP (1) | EP3630816B1 (es) |
JP (1) | JP7216024B2 (es) |
KR (1) | KR20200011933A (es) |
CN (1) | CN110637030B (es) |
AR (1) | AR111840A1 (es) |
AU (1) | AU2018276409A1 (es) |
BR (1) | BR112019022729A2 (es) |
CA (1) | CA3060401A1 (es) |
CL (1) | CL2019003419A1 (es) |
CO (1) | CO2019012329A2 (es) |
EA (1) | EA201992808A1 (es) |
IL (1) | IL270854B2 (es) |
MA (1) | MA48760A (es) |
MX (1) | MX2019014331A (es) |
MY (1) | MY200744A (es) |
PE (1) | PE20200610A1 (es) |
PH (1) | PH12019502602A1 (es) |
TW (1) | TW201906858A (es) |
UA (1) | UA125761C2 (es) |
WO (1) | WO2018220080A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7216024B2 (ja) * | 2017-05-31 | 2023-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍細胞におけるWntシグナル伝達と拮抗するポリペプチド |
GB2578394A (en) | 2017-08-07 | 2020-05-06 | Univ California | Platform for generating safe cell therapeutics |
CA3085782A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Wnt surrogate molecules and uses thereof |
CA3085785A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-lrp5/6 antibodies and methods of use |
CN117946267A (zh) | 2017-12-19 | 2024-04-30 | 瑟罗泽恩奥普瑞汀公司 | 抗卷曲蛋白抗体和使用方法 |
WO2020080941A1 (en) * | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
CN113544150A (zh) * | 2019-02-11 | 2021-10-22 | 瑟罗泽恩公司 | 眼部病症中wnt信号传导的调节 |
EP3946617A1 (en) | 2019-03-29 | 2022-02-09 | Boehringer Ingelheim International GmbH | Anticancer combination therapy |
AU2020329092A1 (en) * | 2019-08-14 | 2022-03-31 | Antlera Therapeutics Inc. | Antibodies that bind to LRP5 proteins and methods of use |
KR20230011226A (ko) * | 2021-07-13 | 2023-01-20 | 인제대학교 산학협력단 | NEURL 유전자, 이를 포함하는 발현벡터 또는 NEURL 단백질을 유효성분으로 포함하는 β-카테닌 과발현으로 인한 암질환 예방 또는 치료용 약학조성물 |
EP4384552A1 (en) * | 2021-08-10 | 2024-06-19 | Heat Biologics, Inc. | Generation and characterization of novel tim-4 binding agents |
CN114702588B (zh) * | 2022-04-27 | 2022-11-22 | 博际生物医药科技(杭州)有限公司 | 抗Nectin-4抗体和双特异性抗体 |
WO2023250402A2 (en) * | 2022-06-22 | 2023-12-28 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3444885B2 (ja) | 1992-08-21 | 2003-09-08 | フリーイェ・ユニヴェルシテイト・ブリュッセル | L鎖欠落免疫グロブリン |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
DE69837542T2 (de) | 1997-04-15 | 2008-01-31 | Merck & Co, Inc. | Ldl-rezeptor |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
EP2067488A1 (en) | 2000-04-12 | 2009-06-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
IL158750A0 (en) | 2001-05-17 | 2004-05-12 | Genome Therapeutics Corp | Reagents and methods for modulating dkk-mediated interactions |
DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1517921B1 (en) * | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
EP1558646A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses thereof |
US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
AU2005293752A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease |
JP5047950B2 (ja) | 2005-05-18 | 2012-10-10 | アブリンクス エン.ヴェー. | 腫瘍壊死因子−アルファに対する改良ナノボディ(商標) |
WO2007027509A2 (en) * | 2005-08-31 | 2007-03-08 | Biogen Idec Ma Inc. | Evaluating and treating scleroderma |
US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
US20100113339A1 (en) | 2006-09-08 | 2010-05-06 | Ablynx N. V. | Serum albumin binding proteins with long half-lives |
JP2010511397A (ja) | 2006-12-05 | 2010-04-15 | アブリンクス エン.ヴェー. | 血清タンパク質と結合可能なペプチド |
US20110091462A1 (en) | 2008-03-05 | 2011-04-21 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
US8217140B2 (en) | 2008-04-17 | 2012-07-10 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
US8716243B2 (en) | 2008-05-28 | 2014-05-06 | St. Jude Childen's Research Hospital | Methods of effecting Wnt signaling through Dkk structural analysis |
BR112012017051A2 (pt) | 2009-12-23 | 2017-12-05 | Esbatech Alcon Biomed Res Unit | método para diminuir a imunogenicidade |
WO2011095545A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx Nv | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
UY33253A (es) | 2010-03-03 | 2011-09-30 | Boehringer Ingelheim Int | Polipéptidos de unión a a-beta |
NZ602040A (en) * | 2010-03-24 | 2014-12-24 | Genentech Inc | Anti-lrp6 antibodies |
EA201291180A1 (ru) * | 2010-05-06 | 2013-05-30 | Новартис Аг | Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) |
MX2012012927A (es) | 2010-05-06 | 2013-05-01 | Novartis Ag | Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
SG192182A1 (en) * | 2011-01-28 | 2013-08-30 | Univ Leland Stanford Junior | Wnt compositions and methods of use thereof |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US8790650B2 (en) | 2011-04-28 | 2014-07-29 | Vanderbilt University | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling |
IN2014CN00373A (es) | 2011-06-23 | 2015-04-03 | Ablynx Nv | |
BR112014003679B1 (pt) | 2011-08-17 | 2022-08-30 | Glaxo Group Limited | Domínio variável de imunoglobulina único, composição farmacêutica, formulação, ácido nucleico isolado ou recombinante, vetor, microorganismo transgênico, e, uso de uma composição farmacêutica |
ES2666856T3 (es) | 2011-11-04 | 2018-05-08 | Novartis Ag | Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media |
KR20140116490A (ko) * | 2012-01-18 | 2014-10-02 | 제넨테크, 인크. | 항-lrp5 항체 및 사용 방법 |
AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
MY200933A (en) * | 2015-12-04 | 2024-01-24 | Boehringer Lngelheim Int Gmbh | Biparatopic Polypeptides Antagonizing Wnt Signaling In Tumor Cells |
JP7216024B2 (ja) * | 2017-05-31 | 2023-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍細胞におけるWntシグナル伝達と拮抗するポリペプチド |
EP3946617A1 (en) * | 2019-03-29 | 2022-02-09 | Boehringer Ingelheim International GmbH | Anticancer combination therapy |
-
2018
- 2018-05-30 JP JP2019565865A patent/JP7216024B2/ja active Active
- 2018-05-30 AR ARP180101427A patent/AR111840A1/es unknown
- 2018-05-30 WO PCT/EP2018/064295 patent/WO2018220080A1/en active Application Filing
- 2018-05-30 AU AU2018276409A patent/AU2018276409A1/en active Pending
- 2018-05-30 EA EA201992808A patent/EA201992808A1/ru unknown
- 2018-05-30 PE PE2019002493A patent/PE20200610A1/es unknown
- 2018-05-30 KR KR1020197033590A patent/KR20200011933A/ko not_active Application Discontinuation
- 2018-05-30 MY MYPI2019006657A patent/MY200744A/en unknown
- 2018-05-30 UA UAA201911920A patent/UA125761C2/uk unknown
- 2018-05-30 EP EP18729376.6A patent/EP3630816B1/en active Active
- 2018-05-30 CN CN201880033136.9A patent/CN110637030B/zh active Active
- 2018-05-30 CA CA3060401A patent/CA3060401A1/en active Pending
- 2018-05-30 BR BR112019022729A patent/BR112019022729A2/pt unknown
- 2018-05-30 US US15/992,345 patent/US11033636B2/en active Active
- 2018-05-30 TW TW107118382A patent/TW201906858A/zh unknown
- 2018-05-30 MX MX2019014331A patent/MX2019014331A/es unknown
- 2018-05-30 MA MA048760A patent/MA48760A/fr unknown
-
2019
- 2019-10-31 CO CONC2019/0012329A patent/CO2019012329A2/es unknown
- 2019-11-20 PH PH12019502602A patent/PH12019502602A1/en unknown
- 2019-11-24 IL IL270854A patent/IL270854B2/en unknown
- 2019-11-25 CL CL2019003419A patent/CL2019003419A1/es unknown
-
2021
- 2021-05-10 US US17/316,042 patent/US20220362393A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3060401A1 (en) | 2018-12-06 |
PH12019502602A1 (en) | 2020-06-08 |
AR111840A1 (es) | 2019-08-21 |
JP7216024B2 (ja) | 2023-01-31 |
TW201906858A (zh) | 2019-02-16 |
US11033636B2 (en) | 2021-06-15 |
EP3630816A1 (en) | 2020-04-08 |
MY200744A (en) | 2024-01-13 |
MA48760A (fr) | 2020-04-08 |
CO2019012329A2 (es) | 2020-01-17 |
AU2018276409A1 (en) | 2019-10-31 |
IL270854B2 (en) | 2023-02-01 |
EP3630816C0 (en) | 2024-03-20 |
BR112019022729A2 (pt) | 2020-05-19 |
KR20200011933A (ko) | 2020-02-04 |
UA125761C2 (uk) | 2022-06-01 |
MX2019014331A (es) | 2020-01-27 |
CN110637030B (zh) | 2024-06-11 |
IL270854B (en) | 2022-10-01 |
JP2020521478A (ja) | 2020-07-27 |
US20180344868A1 (en) | 2018-12-06 |
CL2019003419A1 (es) | 2020-03-27 |
EP3630816B1 (en) | 2024-03-20 |
CN110637030A (zh) | 2019-12-31 |
US20220362393A1 (en) | 2022-11-17 |
WO2018220080A1 (en) | 2018-12-06 |
EA201992808A1 (ru) | 2020-05-14 |
IL270854A (en) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20200610A1 (es) | Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales | |
AR106949A1 (es) | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales | |
AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
PE20190976A1 (es) | Anticuerpos de union a cd3 | |
CL2019001756A1 (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
PE20181322A1 (es) | Anticuerpo anti-pd1 y sus metodos de uso | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
PE20180481A1 (es) | Anticuerpos de union a tau | |
PE20180120A1 (es) | Proteinas de union a icos | |
PE20211284A1 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
PE20181517A1 (es) | Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer | |
AR105724A1 (es) | Anticuerpos anti-bcma (antígeno de maduración de células b), moléculas de unión a antígenos biespecifícas que se unen a bcma y cd3 (determinante agregado 3), y usos de éstas | |
PE20171442A1 (es) | Peptidos y combinacion de peptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
AR087615A1 (es) | Moleculas biespecificas de union a antigeno | |
EA202090275A3 (ru) | Антитела против с5 с улучшенными фармакокинетическими характеристиками | |
EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
EA201591515A1 (ru) | Полипептиды il-22, химерные белки il-22 fc и их применение | |
MX2022015847A (es) | Proteinas de union a cd123 y composiciones y metodos relacionados. |